跳至主要内容
临床试验/ACTRN12611000432910
ACTRN12611000432910尚未招募未知

A Pilot Clinical Study to Evaluate the Potential of AMLAMAX (trademark (TM)) (Emblica Officinalis) Extract on Raising HDL-Cholesterol levels and Decreasing Plasma Amyloid beta Levels in subjective memory complainers with low HDL-C.

Prof Ralph Martins0 个研究点目标入组 167 人开始时间: 2011年4月27日最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
167

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
35 Years 至 65 Years(—)
性别
All

入选标准

  • Inclusion Criteria: The eligibility criteria will be as follows: 1) age 35-65 years, 2) HDL-C levels <1.03 mMol/L in men or <1.29 mMol/L in women 3) triglyceride (TG) levels >1.7 mMol/L.
  • psychometric testing using standardized, validated diagnostic tools.
  • Mini-Mental State Examination (MMSE) score greater than or equal to 24.
  • 2. The classification of SMC will be obtained from a single question, yes/no response from the CAMDEX-R (Do you have any difficulty with your memory?
  • 2.A score greater than or equal to 80-81 (CAMCOG)-R (cognitive component of the CAMDEX-R).
  • 4. a score of below, equal and above age and education norms on the California Verbal Learning Test (CVLT).

排除标准

  • Patients suffering from heart failure, chronic liver disease, eGFR<60 ml/min.

研究者

发起方
Prof Ralph Martins

相似试验

The effect of Amlamax (made from Indian gooseberry)... | 临床试验